(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.45%) $78.03
(0.23%) $2.21
(0.09%) $2 326.30
(0.29%) $27.63
(-0.04%) $988.00
(0.17%) $0.931
(0.43%) $10.95
(0.18%) $0.801
(0.01%) $91.45
Quarter results tomorrow
(amc 2024-05-09)
Expected move: +/- 9.73%
Live Chart Being Loaded With Signals
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process...
Stats | |
---|---|
今日成交量 | 108 479 |
平均成交量 | 341 809 |
市值 | 69.07M |
EPS | $0 ( 2024-05-07 ) |
下一个收益日期 | ( $-0.430 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.37 |
ATR14 | $0.0410 (0.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-27 | Fletcher Aaron G.l. | Sell | 34 731 | Common Stock |
2024-02-28 | Fletcher Aaron G.l. | Sell | 51 608 | Common Stock |
2024-02-29 | Fletcher Aaron G.l. | Sell | 13 686 | Common Stock |
2024-02-27 | Fletcher Aaron G.l. | Sell | 10 620 | Common Stock |
2024-02-28 | Fletcher Aaron G.l. | Sell | 15 780 | Common Stock |
INSIDER POWER |
---|
-63.18 |
Last 98 transactions |
Buy: 4 152 509 | Sell: 1 662 260 |
音量 相关性
Lantern Pharma Inc. 相关性 - 货币/商品
Lantern Pharma Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-174 843 (0.00 %) |
EPS: | $-1.470 |
FY | 2023 |
营收: | $0 |
毛利润: | $-174 843 (0.00 %) |
EPS: | $-1.470 |
FY | 2022 |
营收: | $0 |
毛利润: | $-154 681 (0.00 %) |
EPS: | $-1.300 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.105 |
Financial Reports:
No articles found.
Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。